サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513895

線維筋痛症治療学の世界市場

Fibromyalgia Therapeutics

出版日
ページ情報
英文 263 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
線維筋痛症治療学の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 263 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

線維筋痛症治療学の世界市場は2030年までに38億米ドルに達する見込み

2023年に31億米ドルと推定される線維筋痛症治療学の世界市場は、分析期間2023-2030年にCAGR 3.0%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗てんかん薬薬剤クラス別は、CAGR 2.8%を記録し、分析期間終了時には21億米ドルに達すると予測されます。抗うつ薬クラス別の成長率は、分析期間中CAGR 3.4%と推定されます。

米国市場は8億2,930万米ドルと推定、中国はCAGR 5.0％で成長予測

米国の線維筋痛症治療学市場は、2023年に8億2,930万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億3,620万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは5.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と2.5%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

線維筋痛症治療学-主な動向と促進要因

線維筋痛症は、米国の成人約400万人のQOLに重大な影響を与える慢性疾患であり、主に女性が罹患しています。広範な筋骨格系の痛みに加え、疲労、しばしば「線維性霧」と呼ばれる認知の問題、睡眠障害、刺激に対する過敏性が特徴です。線維筋痛症の診断は複雑で、患者の病歴の徹底的な評価、症状のチェック、他の可能性のある疾患の除外が必要です。線維筋痛症は遺伝的要因に関連することが多く、家族内における有病率が顕著です。線維筋痛症に対する現在の理解と管理は、この衰弱状態に罹患している人々をよりよくサポートするために、一般の人々や専門家の認識を広げる必要があります。

線維筋痛症を管理するための治療的アプローチは多面的であり、中枢神経系による疼痛処理の根本的な不整に対処しながら症状を緩和することに重点を置いています。線維筋痛症に伴う疼痛や気分症状の管理には、プレガバリンやデュロキセチンのようなFDA承認薬が一般的に処方されます。しかし、非ステロイド性抗炎症薬（NSAIDs）、オピオイド、コルチコステロイドは一般的に効果がないです。その他の治療法としては、神経痛に対するガバペンチノイド、睡眠障害に対する鎮静薬、精神症状の管理に対するSNRIやSSRIなどがあります。理学療法、鍼治療、認知行動療法、食生活の改善などの非薬物療法も、包括的な治療計画には欠かせない要素です。これらの戦略は、全体的な身体機能の改善、疼痛の軽減、線維筋痛症患者の生活の質の向上を目的としています。

線維筋痛症治療学の成長は、いくつかの重要な要因によって牽引されています。診断技術の進歩により、線維筋痛症の診断の正確性と適時性が向上し、的を絞った治療の適用が強化されています。ヘルスケアにおけるAIと機械学習の統合は、個別化された治療計画を促進し、治療成果を最適化します。重要な健康指標をモニターするウェアラブル医療技術は、リアルタイムのデータに基づいて治療アプローチをカスタマイズするのに役立っています。さらに、遠隔医療サービスの利用可能性が高まったことで、特に遠隔地の患者にとっては治療へのアクセスが拡大し、治療レジメンのアドヒアランスが向上しています。また、代替療法に対する患者の嗜好の高まりを反映して、非薬物療法へのシフトも顕著です。さらに、線維筋痛症の早期診断と効果的な管理を促進するためには、教育的な取り組みと認知度の向上が不可欠です。また、革新的な治療法の採用を促し、治療をより身近で安価なものにする上で、規制当局の支援や有利な償還政策も重要な役割を果たしています。これらの要因が相まって、線維筋痛症治療学では、よりダイナミックで統合された、患者中心の状況が形成されつつあります。

調査対象企業の例（全22件）

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6917

Global Fibromyalgia Therapeutics Market to Reach US$3.8 Billion by 2030

The global market for Fibromyalgia Therapeutics estimated at US$3.1 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiepileptics Drug Class, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Antidepressants Drug Class segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$829.3 Million While China is Forecast to Grow at 5.0% CAGR

The Fibromyalgia Therapeutics market in the U.S. is estimated at US$829.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$736.2 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Fibromyalgia Therapeutics - Key Trends and Drivers

Fibromyalgia is a chronic condition that significantly impacts the quality of life of about 4 million adults in the United States, primarily affecting women, though not exclusively. It is characterized by widespread musculoskeletal pain accompanied by fatigue, cognitive issues often referred to as "fibro fog," sleep disturbances, and heightened sensitivity to stimuli. The diagnosis of fibromyalgia is complex, typically involving a thorough assessment of patient history, symptom checks, and the exclusion of other potential conditions, given there are no definitive tests for fibromyalgia. The condition is often related to genetic factors, with a noticeable prevalence in families, and can be triggered by significant stress or traumatic events. Current understanding and management of fibromyalgia require a broadening of public and professional perception to better support those affected by this debilitating condition.

The therapeutic approach to managing fibromyalgia is multifaceted, focusing on alleviating symptoms while addressing the underlying irregularities in pain processing by the central nervous system. FDA-approved medications like pregabalin and duloxetine are commonly prescribed to manage pain and mood symptoms associated with fibromyalgia. Non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and corticosteroids, however, are generally ineffective. Other treatments include gabapentinoids for nerve pain, sedatives for sleep disturbances, and SNRIs and SSRIs for managing psychological symptoms. Non-pharmacological treatments such as physical therapy, acupuncture, cognitive behavioral therapy, and lifestyle modifications like dietary changes are also essential components of a comprehensive treatment plan. These strategies aim to improve overall physical function, reduce pain, and enhance quality of life for fibromyalgia patients.

The growth in fibromyalgia therapeutics is driven by several key factors. Advancements in diagnostic technologies have improved the accuracy and timeliness of fibromyalgia diagnosis, enhancing the application of targeted treatments. The integration of AI and machine learning in healthcare facilitates personalized treatment plans, optimizing therapy outcomes. Wearable health technology that monitors vital health metrics has become instrumental in customizing treatment approaches based on real-time data. Additionally, increased availability of telemedicine services has expanded access to care, particularly for patients in remote areas, improving adherence to treatment regimens. There is also a notable shift towards non-pharmacological treatments, reflecting a growing patient preference for alternative therapies. Furthermore, educational initiatives and increased awareness are crucial in promoting early diagnosis and effective management of fibromyalgia. Regulatory support and favorable reimbursement policies also play significant roles in encouraging the adoption of innovative therapies, making treatments more accessible and affordable. Collectively, these factors are shaping a more dynamic, integrated, and patient-centric landscape in fibromyalgia therapeutics.

Select Competitors (Total 22 Featured) -

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Fibromyalgia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness about Chronic Pain Disorders Throws the Spotlight on Fibromyalgia Therapeutics
    • Rising Prevalence of Fibromyalgia Propels Growth in Therapeutics Market
    • Advances in Pain Management Techniques Drive Adoption of New Therapies
    • Expanding Research on Neuropathic Pain Expands Addressable Market Opportunity
    • Innovations in Drug Delivery Systems Generate Demand for Advanced Therapeutics
    • Increasing Focus on Personalized Medicine Accelerates Demand for Targeted Fibromyalgia Treatments
    • Growing Adoption of Complementary and Alternative Medicine (CAM) Sustains Market Growth
    • Shifts in Patient Preferences towards Non-Opioid Treatments
    • Role of Telemedicine in Managing Fibromyalgia Here's the Story
    • Economic Factors and Healthcare Spending Propel Market Expansion
    • Adoption of Digital Health Technologies and Apps Expands Usage of Fibromyalgia Therapies
    • Growing Focus on Patient Education and Support Groups Propel Market Demand
    • Rising Investment in Biotechnology and Pharmaceuticals Strengthens the Business Case for Fibromyalgia Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fibromyalgia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiepileptics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION